Reviewer’s report

**Title:** Tight controlled dose-reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial

**Version:** 1  **Date:** 28 Dec 2016

**Reviewer:** Spyridon Gkalpakiotis

**Reviewer's report:**

Investigators from Netherlands are planning to conduct a clinical trial to compare the dose-reduction of biologics in psoriasis patients with low disease activity (PASI lower than 5) in comparison with a control group who will be in the stable dose according to label of the biologic drug. They chose adalimumab, etanercept and ustekinumab. This is a very interesting idea because indeed some patients in the real clinical practice may be treated with lower dose but still not enough data are available to support this hypothesis. The design of the study is well prepared. I have only one question to the authors:

**Question:**

1) We know that some patients can stay in remission several months after stopping the biologic therapy. Maybe the interval you are planning to follow the patients (1 year) in the reduced dose is short? I can imagine that most of the patients during the 1 year follow up in a lower dose will do OK, but the question is for how long? Do you plan to continue the trial?

**Are the methods appropriate and well described?**

If not, please specify what is required in your comments to the authors.

Yes

**Does the work include the necessary controls?**

If not, please specify which controls are required in your comments to the authors.

Yes

**Are the conclusions drawn adequately supported by the data shown?**

If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal